Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Frits Van Rhee

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Van Rhee, Frits

Item TypeName
Academic Article Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
Academic Article Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
Academic Article Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels.
Academic Article Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
Academic Article Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue.
Academic Article A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Academic Article Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.
Concept Receptors, Interleukin-6
Concept Interleukin-6
Concept Interleukin Receptor Common gamma Subunit
Concept Interleukin-4
Concept Interleukin-2
Academic Article CNTO 328, a Novel- Anti-Interleukin-6 Monoclonal Antibody, is an Active Treatment for Castleman Disease
Academic Article Siltuximab for multicentric Castleman disease.
Academic Article Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Academic Article A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
Academic Article Treatment of Idiopathic Castleman Disease.
Academic Article Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
Academic Article Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
Grant 2004-23: (Protocol C0328T03) A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Administered Biweekly as an Intravenous Infusion
Grant A Randomized, Double blind, Placebo controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportiv
Academic Article Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
Academic Article Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
Grant A Randomized, Double blind, Placebo controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportiv
Grant 2004-23: (Protocol C0328T03) A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Administered Biweekly as an Intravenous Infusion
Academic Article Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling.
Academic Article Siltuximab administration results in spurious IL-6 elevation in peripheral blood.

Search Criteria
  • Interleukin 2